首页> 外文期刊>Travel medicine and infectious disease >Prophylactic efficacy of primaquine for preventing Plasmodium falciparum and Plasmodium vivax parasitaemia in travelers: A?meta-analysis and systematic review
【24h】

Prophylactic efficacy of primaquine for preventing Plasmodium falciparum and Plasmodium vivax parasitaemia in travelers: A?meta-analysis and systematic review

机译:预防血管血管疟原虫和疟原虫疟原虫在旅行者中的预防疗效:a?荟萃分析和系统审查

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Abstract Background With increased international travel over the world the need for safe and effective chemoprophylaxis for malaria is as great as ever. The choice of regimen is difficult, as effectiveness should be weighted against potential adverse effects. Although, some studies have reported high prophylactic efficacy of primaquine, there is no comprehensive evidence comparing its prophylactic effectiveness as well as toxicity. To fill the gap, this systematic review and meta-analysis study was carried out. Methods Using MeSH terms, 756 records were detected through searching “Pubmed”, “Embase”,”Web of Science”and “Cochrane” databases. From these,7 relevant full-text articles with 14 comparisons for final quantitative meta-analysis were included in our review. In order to make a comparison between the studies, Risk Ratios(RRs) and their 95% confidence intervals(CIs) were estimated. Results Overall,74% reduction in the incidence of parasitaemia by primaquine versus other prophylactic regimens was estimated(RRoverall?=?0.26, CI 95%:0.16–0.41--RRvivax?=?0.16, CI 95%:0.07–0.36--RRfalciparum?=?0.31, CI 95%:0.18–0.55). The incidence rate ratios for adverse effects showed no statistically significant difference between primaquine and control groups (p??0.05). Conclusions For persons without G6PD deficiency, who are not pregnant, primaquine is the most effective presently available prophylactic for P. vivax malaria and comparable to such regimens as doxycycline, mefloquine and atovaquone-proguanil for the prevention of P. falciparum malaria. ]]>
机译:摘要背景随着世界各地国际旅行的增加,对安全有效的疟疾化学预防的需求一如既往。方案的选择是困难的,因为有效性应与潜在的不良反应相权衡。尽管一些研究报告了伯氨喹的高预防效果,但没有综合证据比较其预防效果和毒性。为了填补这一空白,进行了这项系统回顾和荟萃分析研究。方法使用网格术语,通过搜索“Pubmed”、“Embase”、“科学网”和“Cochrane”数据库,检测756项记录。我们的综述中包括7篇相关全文文章和14篇最终定量荟萃分析比较。为了对研究进行比较,估计了风险比(RRs)及其95%置信区间(CI)。结果总体而言,与其他预防方案相比,伯氨喹使寄生虫病的发病率降低了74%(RRoverall?=0.26,CI 95%:0.16–0.41——间日疟原虫?=0.16,CI 95%:0.07–0.36——恶性疟原虫?=0.31,CI 95%:0.18–0.55)。副作用的发生率比率在伯氨喹组和对照组之间无统计学显著差异(p>0.05)。结论对于没有G6PD缺乏症且未怀孕的人,伯氨喹是目前可用的间日疟最有效的预防药物,在预防恶性疟方面可与强力霉素、甲氟喹和阿托伐喹等方案相媲美。]]>

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号